/**/ RNS Number : 2319E IQ-AI Limited 09 March 2022 FOR IMMEDIATE RELEASE IQ-AI LIMITED (“IQ-AI” or the “Company”) IQAI’s Sponsored Phase I Clinical Trial is Open Milwaukee – 9 March 2022: IQ-AI Limited (OTCQB: IQAIF) (LSE: IQAI) is pleased to announce that the sponsored Phase I clinical trial for oral gallium maltolate (GaM)
Milwaukee – 2 November 2021: IQ-AI Limited (LSE: IQAI) (OTCQB: IQAIF), a developer and manufacturer of medical image processing platforms that have led to effective therapeutic strategies for brain tumor and other patients, today announced the University of Texas MD Anderson Cancer Center (Houston, TX) is the latest brain cancer center to purchase an annual
Milwaukee – 1 October 2021: IQ-AI Limited (LSE: IQAI) (OTCQB: IQAIF), a developer and manufacturer of medical image processing platforms announced a recent publication in Neurosurgery Open that illustrates the clinical impact of its neuro oncology software solutions for both neurosurgery and tissue diagnosis of high-grade brain tumors.
Milwaukee – 22 September 2021: IQ-AI Limited (LSE: IQAI) (OTCQB: IQAIF), a developer and manufacturer of medical image processing platforms that have led to effective therapeutic strategies that prolong survival and improve the quality of life in brain tumor and other patients, today announced it has been awarded a European Patent for “Multiparameter Perfusion Imaging
Elm Grove, WI, June 23, 2021 – IQ-AI subsidiary Imaging Biometrics (IB) was awarded a U.S. patent for its artificial intelligence (AI) software technology that eliminates the need for gadolinium-based contrast agents (GBCAs) in medical imaging exams. A zero-dose exam potentially offers remarkable benefits which include a more comfortable patient experience, more productive radiology departments,
Elm Grove, WI, April 20, 2021 – IQ-AI, Ltd (publicly traded on the London Stock Exchange as IQAI) will finance a Phase I clinical trial to evaluate the safety and efficacy of Gallium Maltolate (GaM) in the treatment of Glioblastoma Multiforme (GBM). Scheduled to start this summer, the trial will consist of approximately 20 patients
Birmingham, Ala. Nov. 16, 2020 – AI Metrics, LLC, a medical imaging startup focused on leveraging artificial intelligence to improve patient care, announced today that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for the company’s LSN (Liver Surface Nodularity) module. This first FDA clearance represents a significant milestone for AI Metrics, where
